Ocular involvement in children with beta-thalassemia major
DOI:
https://doi.org/10.2478/AMB-2024-0048Keywords:
beta-thalassemia, children, ocular abnormalities, ferritinAbstract
Aim: Thalassemia is a severe genetic blood disorder, and several organs, including eyes, can be affected. The mechanism of ocular abnormalities in thalassemia is multifactorial; one of them is regular blood transfusion, which can cause iron overload. Ocular abnormalities can also occur because of the side effects of iron chelators. This study evaluated ocular involvement in children with Beta-thalassemia major and its association with serum ferritin levels. Methods: A cross-sectional study was undertaken at the Thalassemia daycare center in a tertiary referral hospital in Medan. All patients’ hemoglobin was measured before transfusion, and serum ferritin levels were measured at six-month intervals. A Pediatric Ophthalmologist carried out the ophthalmological assessment, which included a detailed history of visual problems and visual acuity testing. Fisher’s Exact test and Spearman test were used for
statistical calculation. Results: Thirty-seven beta-thalassemia major children ranging from three to 18 years old. Visual acuity, anterior segment, fundus, and retina were evaluated. Ophthalmologic examinations showed that ocular involvement increased with age. Visual acuity was reduced in 16.2% of the subjects. Papilledema was the most common ocular finding among the subjects (13.5%), followed by cataracts (8.1%) and optic atrophy (8.1%). A significant correlation between blood transfusion volume and serum ferritin levels was found. Conclusion: Ocular involvement was found in more than half of the subjects in this study. However, regular ophthalmologic
evaluations by serum ferritin examination were required to detect early alterations in their visual system for a better quality of life.
References
Vichinsky EP. Changing patterns of thalassemia worldwide. In: Ann N Y Acad Sci. 1054.; 2005:18-24.
Taher AT, Saliba AN. Iron overload in thalassemia: Different organs at different rates. Hematology. 2017; 2017(1):265-271.
Taher A, Bashshur Z, Shamseddeen WA, et al. Ocular findings among thalassemia patients. Am J Ophthalmol. 2006;142(4):704-705.
Thalassaemia International Federation. Guidelines for the Management of Transfusion Dependent Thalassemia (TDT); 2014.
Thuangtong A, Wiriyaudomchart S, Rungsiri K. Incidence of ocular toxicity from iron chelating agents at Siriraj Hospital. Siriraj Med J. 2020; 72(3):209-213.
Gartaganis S, Ismiridis K, Papageorgiou O, et al. Ocular abnormalities in patients with β thalassemia. Am J Ophthalmol. 1989; 108(6):699-703.
Wong RW, Richa DC, Hahn P, et al. Iron toxicity as a potential factor in AMD. Retina. 2007; 27(8):997-1003.
Merchant RH, Punde H, Thacker N, et al. Ophthalmic Evaluation in Beta-Thalassemia. Indian J Pediatr. 2017;84(7):509-514.
Jafari R, Heydarian S, Karami H, et al. Ocular abnormalities in multi-transfused beta-thalassemia patients. Indian J Ophthalmol. 2015;63(9):710-715.
Taneja R, Malik P, Sharma M, et al. Multiple transfused thalassemia major: Ocular manifestations in a hospital-based population. Indian J Ophthalmol. 2010; 58(2):125-130.
Gosai D, Mehariya K, Gosai J. Study of ocular manifestations in children of thalassemia. Int J Res Med Sci. 2014; 2(2):695-698.
Haghpanah S, Zekavat OR, Bordbar M, et al. Ocular findings in patients with transfusion-dependent β-thalassemia in southern Iran. BMC Ophthalmol. 2020; 20(1):376.
Loh A, Hadziahmetovic M, Dunaief JL. Iron homeostasis and eye disease. Biochim Biophys Acta - Gen Subj. 2009; 1790(7):637-649.
Wood JC. Diagnosis and management of transfusion iron overload: The role of imaging. Am J Hematol. 82.; 2007:1132-1135.
Susanah S, Idjradinata PS, Sari NM, et al. Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia. Sadikot R, ed. Biomed Res Int. 2020; 2020:8185016.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 B. Lubis, S. M. Lubis, B. D. Sulistyowati (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.